We thus chose the former approach for PIT-063, using a TP53 stop-gain mutation that was present at 33% in the tumor, but only at 0.9% in plasma, thereby confirming our hypothesis that very little ctDNA is present in this patient's ccfDNA. The gene discussed is TP53; the disease is neoplasm.